XML 16 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Insider Trading Arrangements
 3 Months Ended
Jun. 30, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

Other than as disclosed below, during the three months ended June 30, 2024, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.

 

On June 17, 2024, Maria Arantxa Horga, M.D., our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement, as defined in Item 408(a) of Regulation S-K. This arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to 67,198 shares of the Company’s common stock. The exact number of shares of common stock that will be sold is not determinable and will depend on the number of shares sold to cover tax withholding obligations in connection with the vesting of 41,534 restricted stock units previously granted. The 10b5-1 plan expires on June 15, 2025.
Non-Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Terminated false
Maria Arantxa Horga  
Trading Arrangements, by Individual  
Name Maria Arantxa Horga, M.D.,
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date June 17, 2024
Rule 10b5-1 Arrangement Terminated false
Expiration Date June 15, 2025
Shares of Common Stock | Maria Arantxa Horga  
Trading Arrangements, by Individual  
Aggregate Available 67,198
Vesting of Restricted Stock Units | Maria Arantxa Horga  
Trading Arrangements, by Individual  
Aggregate Available 41,534